The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
DiaMedica Inc. (TSXV:DMA) announced a development update on its lead product candidates, DM199 and DM204. The Company also announced it intends to expand the testing of DM199 in diabetic kidney disease patients while also developing DMDx, a companion diagnostic for kidney disease.
DiaMedica Inc. (TSXV:DMA) announced a development update on its lead product candidates, DM199 and DM204. The Company also announced it intends to expand the testing of DM199 in diabetic kidney disease patients while also developing DMDx, a companion diagnostic for kidney disease. DiaMedica is a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications.
Mr. Rick Pauls, President and CEO of DiaMedica explained:
We believe there is a significant need for more effective therapies for diabetes and diabetic kidney disease, particularly as the prevalence of these diseases rises. We look forward to further advancing the development of our programs for diabetes while expanding into diabetic kidney disease and other associated diseases with DM199.
Click here to view the full press release.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.